Needham cuts target for ACADIA Pharmaceuticals stock from USD 40.00 to USD 35.00
Published on 10/02/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Needham lowered its price target for ACADIA Pharmaceuticals stock from USD 40.00 to USD 35.00 on September 24, 2026, while maintaining a Buy rating, according to Investing.com. The revision followed mixed results from the RADIANT study of remlifanserin in Alzheimer disease psychosis.
Trial results reset expectations
The Phase 2 study missed its primary endpoint for both tested doses, while a post hoc subgroup analysis showed better results among patients with higher baseline severity, Investing.com reported on September 25, 2026. Goldman Sachs separately reiterated a Sell rating and a USD 17.00 target after the trial result, according to Investing.com on September 24, 2026.
Revenue growth cushions the setback
ACADIA reported USD 308.00 million in revenue for the second quarter of 2026, up 16.40 percent from the same quarter a year earlier. Quarterly earnings per share reached USD 0.18 versus the USD 0.07 consensus, a USD 0.11 comparison advantage, according to MarketBeat on October 1, 2026. The figures give the commercial portfolio a stronger near-term base while the pipeline now carries greater clinical uncertainty.
Acadia says its commercial portfolio includes FDA-approved treatments for Parkinson disease psychosis and Rett syndrome, with additional mid- and late-stage programs in neurological disorders, according to Acadia Pharmaceuticals. Its investor-relations page identifies the second-quarter 2026 results as the latest quarterly report.
ACAD stock trades near its yearly low
ACADIA Pharmaceuticals stock was trading at EUR 17.86 at Lang & Schwarz on October 2, 2026 at 2:10 p.m. CEST, up 0.96 percent versus the prior close of EUR 17.69 on October 1, 2026. The primary Nasdaq listing showed a USD 19.59 to USD 30.96 52-week range and a USD 3.4 billion market capitalization as of October 1, 2026.
ACADIA Pharmaceuticals market snapshot
- Company: ACADIA Pharmaceuticals Inc.
- ISIN: US0042251084
- Ticker: ACAD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 2, 2026, 2:10 p.m. CEST): EUR 17.86
- Change versus prior close: plus 0.96 percent
- Prior close Lang & Schwarz (October 1, 2026): EUR 17.69
- Market capitalization: USD 3.4 billion (as of October 1, 2026)
- 52-week range: USD 19.59-30.96 (as of October 1, 2026)
- Sector / Industry: Healthcare / Biotechnology
